Alterations in DNA methylation, both in specific genes and overall in the genome, have been recognised as among the most important molecular alterations in tumour tissue ([@bib35]; [@bib10]). Global hypomethylation and regional hypermethylation appear to be hallmarks of human tumours: although regional hypermethylation is clearly observed in multiple distinct genomic regions harbouring tumour-suppressor and mutator genes regulating their transcriptional activities ([@bib34]), global hypomethylation is known to cause genomic instability, reactivation of transposable elements, and loss of imprinting, thereby contributing to the development of cancer ([@bib10]). As one example, DNA from breast cancer tissues has been shown to be hypomethylated compared with that from normal tissues ([@bib30]; [@bib16]).

Recently, epidemiologic studies have investigated whether the global methylation level in peripheral blood cells is a useful biomarker for cancers ([@bib32]). Although most of these potential associations have been examined in case--control studies and require careful interpretation of causality, results have suggested that a lower level of global methylation is associated with an increased risk of a number of cancers, including colorectal adenoma ([@bib28]; [@bib23]), head and neck squamous cell cancer ([@bib13]), bladder cancer ([@bib25]), gastric cancer ([@bib12]) and breast cancer ([@bib7]). Global methylation level may serve as an integrated and intermediate measure for cancer development, reflecting the accumulation of multiple reversible and irreversible factors including age, sex, lifestyle, and environmental exposures, and genetic polymorphisms ([@bib41]; [@bib43]).

Folate and related vitamins B are involved in one-carbon metabolism, which has an important role in DNA synthesis, replication and repair and in DNA methylation ([@bib17]). Several reports have shown that a lack of folate or related nutrients causes DNA hypomethylation in humans ([@bib18]; [@bib29]). Moreover, epidemiological studies have shown that folate intake might protect against the development of some cancers ([@bib1]; [@bib22]), albeit that this association is still controversial ([@bib5]; [@bib31]; [@bib19]; [@bib24]). Although our data showed no significant association of folate, vitamins B2, B6, and B12, and single-nucleotide polymorphisms (SNPs) on methylenetetrahydrofolate reductase (*MTHFR*), methionine synthase (*MTR*) or methionine synthase reductase (*MTRR*) with breast cancer risk ([@bib24]), these factors may affect the association of global methylation with breast cancer risk.

Global methylation has been measured by several methods, such as measurement of the methylation level of the specific repetitive sequences *Alu* or LINE-1. In the present study, we adopted the LUminometric Methylation Assay (LUMA), which measures DNA methylation in CCGG sequences and provides a robust estimation of overall 5-mC content in dinucleotide CpG sites in the whole genome ([@bib20], [@bib21]). LUminometric Methylation Assay has been used in studies of the association of global methylation and breast cancer in other ethnic groups, which showed inconsistent results ([@bib8]; [@bib40]). Here, we examined global methylation of peripheral blood leukocyte DNA by LUMA in patients with breast cancer and matched controls in Japan.

Materials and Methods
=====================

Study subjects
--------------

This multicenter, hospital-based case--control study of breast cancer was conducted from May 2001 to September 2005 at four hospitals in Nagano Prefecture, Japan. Details of the study have been described previously ([@bib14]; [@bib24]). Briefly, the case subjects were a consecutive series of women aged 20--74 years with newly diagnosed, histologically confirmed invasive breast cancer who were admitted to one of the four hospitals during the survey period. Of 412 eligible patients, 405 (98%) agreed to participate. Healthy controls were selected from medical checkup examinees in two of the hospitals and confirmed not to have any cancer, with one control matched for each case by age (within three years) and residential area (city or regional area) during the study period. Among the potential control subjects, one declined to participate and two refused to provide blood samples. Consequently, written informed consent was obtained from 405 matched pairs. The study protocol was approved by the Institutional Review Board of the National Cancer Center, Tokyo, Japan.

Data collection
---------------

Participants were asked to complete a self-administered questionnaire, which included questions on demographic characteristics, anthropometric factors, smoking habit, family history of cancer, physical activity, medical history, and menstrual and reproductive history. Information for case subjects was obtained on admission to the hospital. Dietary habits were investigated using a 136-item semi-quantitative food-frequency questionnaire (FFQ), which was developed and validated in a Japanese population ([@bib24]). In the FFQ, participants were questioned about how often they consumed the individual food items (frequency of consumption), as well as relative sizes compared with standard portions. Daily food intake was calculated by multiplying frequency by standard portion and relative size for each food item in the FFQ. Daily intakes of nutrients were calculated using the Fifth Revised and Enlarged Edition of the Standard Tables of Food Composition in Japan ([@bib33]). We previously confirmed that the questionnaire\'s assessment of intake of folate and vitamins B2, B6, and B12 was valid ([@bib24]).

Participants provided blood samples at the time they returned their self-administered questionnaire. Whole blood was collected in a 7-ml EDTA-2Na vacutainer, and serum aliquots from the vacutainer tube with clot accelerators were stored at --80 °C until analysis.

Laboratory analysis
-------------------

Genomic DNA was extracted from the peripheral blood using a Qiagen FlexiGene DNA Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol, followed by further purification by phenol-chloroform extraction and ethanol precipitation.

Global DNA methylation was quantified by LUMA. Three hundred nanograms of Genomic DNA was cleaved with *Hap*II+*Eco*RI or *Msp*I+*Eco*RI in two separate 200-*μ*l reactions containing 2 *μ*l of 10 × T buffer (330 m[M]{.smallcaps} Tris-acetate, 100 m[M]{.smallcaps} Mg-acetate, 660 m[M]{.smallcaps} K-acetate, 5 m[M]{.smallcaps} dithiothreitol), 2 *μ*l of 0.1% BSA, and 5 U of each of the restriction enzymes. The reactions were set up in a PSQ 96 Plate Low (Qiagen) and incubated at 37 °C for 1 h. Then, 20 *μ*l of annealing buffer containing 200 m[M]{.smallcaps} Tris-acetate and 50 m[M]{.smallcaps} Mg-acetate, pH 7.6, was added to the cleavage reactions, and samples were assayed using the PSQ96MA system (Biotage AB, Uppsala, Sweden). The instrument was programmed to add dNTPs in six steps as follows: step 1, dATP*α*S; step 2, a mixture of dGTP+dCTP; step 3, dTTP; step 4, a mixture of dGTP+dCTP; step 5, water; and step 6, dATP. Peak heights were calculated using the PSQ96 MA software (Biotage AB). The *Hpa*II/*Eco*RI and *Msp*I/*Eco*RI ratios were measured as (dGTP+dCTP)/dATP for each reaction. The *Hpa*II/*Msp*I ratio was then calculated as (*Hpa*II/*Eco*RI)/(*Msp*I/*Eco*RI), which corresponds to the proportion of unmethylated CCGG. In this paper, we defined 1-*Hpa*II/*Msp*I as methylation level. Restriction enzymes (*Hap*II, *Msp*I, and *Eco*RI) were purchased from Takara Bio (1053A, 1150A, and 1040A, respectively; Shiga, Japan). PyroMark Gold Q96 Reagents for pyrosequencing were purchased from Qiagen (972804). DNA quantification was performed using the Quan-iT PicoGreen dsDNA reagent and kit (P7581, Invitrogen, Carlsbad, CA, USA). [Figure 1](#fig1){ref-type="fig"} shows typical Pyrosequencing data by LUMA. The paired samples from cases and matched controls were randomly placed on each plate. The intra-assay coefficients of variation from 20 replications were 6.4% (mean=0.74, standard deviation (s.d.)=0.017).

Five SNPs in *MTHFR* (rs1801133 and rs1801131), *MTR* (rs1805087), and *MTRR* (rs10380 and rs162049) were genotyped by TaqMan SNP Genotyping Assays developed by Applied Biosystems (Foster City, CA, USA). Genotype frequencies were tested for deviation from the Hardy--Weinberg equilibrium with the *χ*^2^ test as quality control for genotyping (all *P* values \>0.05).

Statistical analysis
--------------------

Age-adjusted mean and proportions of baseline characteristics were calculated in case and control subjects. Dietary intakes were adjusted for total energy intake using the residual method ([@bib36]; [@bib37]). Characteristics were compared using the Cochran--Mantel--Haenszel test with matched paired strata for categorical variables and the paired *t*-test for continuous variables.

Global methylation levels were divided into tertiles based on the distribution of methylation levels among controls. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using a conditional logistic regression model stratified by matched pairs (age and residential area) and adjusted for family history of breast cancer, smoking status, menopausal status, physical activity, number of births, energy-adjusted folate intake, vitamin supplement use, and alcohol drinking. Statistical significance was evaluated with the Wald test. Tertile categories were used as a continuous variable to evaluate linear trends for global methylation levels. Polytomous logistic regression was performed to evaluate the association between methylation level and the hormone receptor status of breast cancer, in which the matching factors are included in the model as covariates. A Wald test for heterogeneity was performed to examine the differences in associations of methylation level and breast cancer risk according to hormone receptor status in breast cancer. Subgroup analysis was performed according to menopausal status, smoking status, intake of folate and vitamins B2, B6, and B12, alcohol drinking, and five SNPs on *MTHFR*, *MTR,* or *MTRR*. A *t*-test was performed to examine whether global methylation levels differed by these factors in controls. Effect modification was tested using a logistic regression model with the interaction term. All *P* values were two-sided, with a *P* value of 0.05 considered statistically significant. We used SAS software (version 9.3, SAS Institute, Cary, NC, USA) for all analyses.

Results
=======

After exclusion of subjects who reported extremely low or high total energy intake (\<500 or ⩾4000 kCal) or had no DNA sample, 384 pairs were included in the present analyses.

[Table 1](#tbl1){ref-type="table"} shows the characteristics of the study population. The proportion of women with a family history of breast cancer, ever smokers, and vitamin supplement users was higher in cases than controls, whereas the proportion of those with moderate physical activity in the past 5 years, and high energy-adjusted dietary intake of vitamins B2, B6, B12, and folate was higher in controls.

The mean of global methylation levels was significantly lower in cases (68.9% 95% CI=68.5--69.3%) than controls (70.2% 95% CI=69.8--70.5%). [Table 2](#tbl2){ref-type="table"} shows the association between global methylation level and breast cancer risk, adjusted for the potential confounders. Lower levels of global methylation were associated with a significantly increased risk of breast cancer (trend OR=1.68; 95% CI=1.35--2.09; *P* value for trend=2.8 × 10^−6^). We confirmed that the associations did not substantially change using the models, which incorporated the other factors, including body mass index, age at menarche, and history of benign breast disease (trend OR=1.66; 95% CI=1.33--2.07), or vitamin B2, B6, and B12 (trend OR=1.70; 95% CI=1.37--2.13). Compared with women in the highest tertile of global methylation level, ORs for those in the second and lowest tertiles were 1.87 (95% CI=1.20--2.91) and 2.86 (95% CI=1.85--4.44), respectively. There was no significant heterogeneity in the associations of global hypomethylation and breast cancer according to either estrogen receptor status in breast cancer (*P* value for heterogeneity test=0.155) or progesterone receptor status (*P* value for heterogeneity test=0.762; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). We also evaluated the effect modification of menopausal status and known or probable factors involved in DNA methylation or folate metabolism on the association between global methylation level and breast cancer risk. Of these factors, methylation levels were significantly different according to alcohol drinking ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). As shown in [Table 3](#tbl3){ref-type="table"}, no significant interaction was observed. In each subgroup, a low level of global methylation tended to be associated with an increased risk of breast cancer.

Discussion
==========

In this case--control study among Japanese women, we found that low levels of global methylation were associated with a significantly increased risk of breast cancer, regardless of the hormone receptor status of the tumour. These associations were not modified by menopausal status, or lifestyle/dietary or genetic factors, which are known to be involved in DNA methylation metabolism, and were analysed in this study. These findings suggest that the global methylation level in leukocyte DNA is a potential biomarker of breast cancer risk.

Our findings are consistent with recent meta-analysis reports ([@bib4]; [@bib38]) and two retrospective case--control studies for breast cancer ([@bib7]; [@bib6]). Our present and these recent studies also suggest that the mechanisms underlying the associations of global hypomethylation and breast cancer might not be substantially influenced by hormonal factors ([@bib7]; [@bib15]). In addition, findings of associations between the global hypomethylation of leukocyte DNA and the risk of several other cancers might suggest that hypomethylation in leukocyte DNA is a common etiology for cancers of multiple different sites.

In contrast, findings from retrospective case--control studies for breast cancer using LUMA, including our study, have been inconsistent. [@bib40] reported the opposite associations to our findings, namely that LUMA methylation levels were higher in cases than in controls, whereas [@bib8] reported no difference in LUMA methylation levels between affected and unaffected sisters. Interestingly, the distribution of LUMA methylation levels in the population-based study of [@bib40] was quite different from those in the other two studies, with means (s.d.s) of LUMA global methylation levels of 57.3% (15.7%) in cases and 52.4% (16.7%) in controls. Thus, most of our subjects were in their highest level category. In contrast, the sibling design study in a high-risk population showed a relatively similar range of LUMA methylation levels to ours, with the affected and unaffected sisters having mean (s.d.s) LUMA methylation levels of 67.1% (7.6%) and 67.5% (7.3%), respectively ([@bib8]). These different results from independent studies may indicate the importance of considering lifestyle and host characteristics in evaluating the associations between global methylation in peripheral blood and cancers. It has been suggested that global methylation in peripheral blood may vary with race/ethnicity and certain lifestyle factors ([@bib41]; [@bib43]), suggesting that these factors can affect the associations between global methylation and breast cancer risk. These differences might also have been impacted by differences in the protocols of the LUMA method.

Interpreting possible causal relationships in our findings should be done with caution, as blood samples were collected after the diagnosis of cancer. In particular, associations reported in recent studies, which used pre-diagnostic blood DNA for other cancers, were inconsistent with those from retrospective studies ([@bib26]; [@bib2]). In any case, an explanation for the significantly lower global methylation in breast cancer cases remains speculative. Global methylation levels vary with different blood cell types ([@bib39]), although information on the proportion of leukocyte fraction was not available in the present study. Further, the relative proportion of leukocyte fractions may be altered in cancer patients ([@bib32]). It is also theoretically possible that we captured circulating tumour cells or tumour-derived plasma-free DNA (or both; [@bib42]; [@bib3]), which represent global hypomethylation in breast cancer tissues, albeit that these tumour-derived DNAs should be present in only very minute amounts in peripheral blood samples.

Furthermore, a recent prospective study showed LINE-1 hypomethylation was associated with a significantly increased risk of breast cancer ([@bib9]). In addition, a second study, which included prevalent and incident cancer cases, suggested that global hypomethylation in peripheral blood mononuclear cells may be a useful biomarker for either early detection or cancer risk ([@bib11]). Although the relationship of methylation status between tumour cells and normal cells, including blood cells, remains unclear ([@bib6]), global hypomethylation may represent an integrated exposure signature of multiple known and unknown endogenous and exogenous carcinogenic factors ([@bib41]; [@bib43]), which in turn suggests that changes in the global methylation status of leukocytes may be an intermediate step in the causal pathway for breast cancer. It would be interesting to follow time changes in global methylation levels in individuals before and during the course of cancer development in large prospective studies.

In addition to its retrospective case--control design, the present study has several other limitations. We observed significant differences between cases and controls in the several factors, which were reported to be associated with breast cancer or global methylation levels ([@bib27]). However, adjustment for these factors had minimal influence on the association, suggesting little potential for residual confounding. Also, the matched controls were selected from medical checkup examinees; these people may have been health conscious and not representative of the general population, which would have led to selection bias. Because a standard method for assessing global methylation level has not been established, quality control in detecting relatively small differences in global methylation level in peripheral blood leukocytes hinders or prevents comparison among studies with different analytical methods. For instance, previous studies reported that methylation levels in LINE-1 were not correlated with 5-mdC levels or global methylation by LUMA ([@bib7]; [@bib40]); and methylation of the retrotransposon elements (e.g., LINE-1) may not be a reliable surrogate measure of global methylation and may have its own biological functions ([@bib32]). The most appropriate assay for epidemiologic research remains to be determined ([@bib39]; [@bib38]). Moreover, our sample size was limited, and the results of subgroup analysis and interaction tests should be interpreted carefully.

In summary, our results suggest that global methylation in leukocyte DNA as analysed by LUMA may be a useful biomarker of breast cancer. The present and previous studies warrant large-scaled prospective studies to elucidate the complex relationship among potential risk factors, changes in global methylation, and breast cancer development.
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![**Typical pyrograms in LUMA assay of DNA cleaved with *Hap*II+*EcoR*I (left panels) and *Msp*I+*EcoR*I (right panels).** Methylation levels are derived from 1---{*Hpa*II (C+G)/*Eco*RI(A)}/{*Msp*I(C+G)/*Eco*RI(A)}. Genomic DNAs from (**A**) K-562 cells, (**B**) Daudi cells, and (**C**) normal peripheral blood leukocytes.](bjc2014223f1){#fig1}

###### Characteristics of the study population

                                                                                     **Controls (*****n*****=384)**   **Cases (*****n*****=384)**   ***P*** **value**[a](#t1-fn2){ref-type="fn"}
  ---------------------------------------------------------------------------------- -------------------------------- ----------------------------- ----------------------------------------------
  Methylation level by the LUMA method (%), mean (s.d.)[b](#t1-fn3){ref-type="fn"}   70.2 (3.4)                       68.9 (3.5)                    \<0.01
  Age (years), mean (s.d.)                                                           54.1 (10.3)                      53.9 (10.7)                   0.07
  Postmenopausal women, %                                                            64                               56                            \<0.01
  Number of births (⩾4 births), %                                                    3                                2                             0.64
  Family history of breast cancer, %                                                 6                                11                            0.02
  Smoking (ever smoker), %                                                           7                                20                            \<0.01
  Alcohol drinking (⩾1/week), %                                                      29                               26                            0.28
  Moderate physical activity past 5 years (yes), %                                   39                               32                            0.03
  Vitamin supplement user, %                                                         12                               18                            0.02
  Age at menarche (years), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                    13.2 (1.7)                       13.4 (1.7)                    0.09
  History of benign breast disease, %                                                8                                12                            0.03
  Body mass index (kg m^−2^), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                 22.9 (3.2)                       22.7 (3.4)                    0.25
  **Dietary intake[c](#t1-fn4){ref-type="fn"}**                                                                                                     
  Vitamin B1 (mg per day), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                    1.1 (0.3)                        1.1 (0.3)                     0.13
  Vitamin B2 (mg per day), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                    1.6 (0.4)                        1.5 (0.4)                     0.01
  Vitamin B6 (mg per day), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                    1.6 (0.3)                        1.5 (0.3)                     0.04
  Vitamin B12 (*μ*g per day), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                 8.7 (3.5)                        8.3 (3.1)                     0.03
  Folate (*μ*g per day), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                      439 (150)                        415 (132)                     \<0.01
  Alcohol (ethanol per week), mean (s.d.)[b](#t1-fn3){ref-type="fn"}                 10.3 (24.0)                      8.1 (16.5)                    0.12

Abbreviations: LUMA= LUminometric Methylation Assay; s.d.=standard deviation.

*P* value by the Cochran--Mantel--Haenszel test with matched-pair strata for percent or paired *t*-test for mean.

Adjusted for age.

Energy-adjusted intake by the residual method.

###### Association between global methylation level and breast cancer risk

                                                                  **Methylation level**                                                              
  -------------------------------------------------------------- ----------------------- ------------------- ------------------- ------------------- --------------
  Cases/controls                                                         69/128                125/128             190/128                            
  Stratified OR (95% CI)[a](#t2-fn1){ref-type="fn"}                      1 (Ref)          1.70 (1.16--2.50)   2.67 (1.83--3.88)  1.63 (1.35--1.96)   2.9 × 10^−7^
  Multivariate adjusted OR (95% CI)[b](#t2-fn2){ref-type="fn"}           1 (Ref)          1.87 (1.20--2.91)   2.86 (1.85--4.44)  1.68 (1.35--2.09)   2.8 × 10^−6^

Abbreviations: CI=confidence interval; OR=odds ratio; Ref=reference.

Stratified by matched pairs.

Adjusted for family history of breast cancer (no, yes), smoking (never, past, current), menopausal status (no, yes), physical activity in the last 5 years (no, ⩽2 days per week, ⩽4 days per week, ⩾5 days per week), number of births (0, 1, 2, 3, ⩾4), vitamin use (no, yes), folate intake (continuous), alcohol drinking (non-drinker, occasional drinker, regular drinker of \<150 g ethanol per week, regular drinker of ⩾150 g ethanol per week), and stratified by matched pairs.

###### Subgroup analysis of the association between global methylation level and breast cancer risk

                                    **Trend**                                     
  -------------------------------- ----------- ------ ------------ -------------- ------
  **Menopausal status**                                                           
  Premenopausal                      173/133   1.53    1.12--2.09   7.2 × 10^−3^   
  Postmenopausal                     211/251   1.78    1.38--2.30   8.1 × 10^−6^  0.46
  **Smoking**                                                                     
  Never                              304/354   1.66    1.35--2.05   1.6 × 10^−6^   
  Ever                                76/28    1.82    0.99--3.36      0.054      0.78
  **Folate (***μ***g per day)**                                                   
  ⩽407.4                             210/192   1.55    1.18--2.03   1.6 × 10^−3^   
  \>407.4                            174/192   1.83    1.37--2.45   4.0 × 10^−5^  0.41
  **Vitamin B2 (mg per day)**                                                     
  ⩽1.5                               230/192   1.47    1.13--1.91   4.1 × 10^−3^   
  \>1.5                              154/192   1.97    1.45--2.66   1.1 × 10^−5^  0.15
  **Vitamin B6 (mg per day)**                                                     
  ⩽1.5                               208/192   1.76    1.33--2.33   8.0 × 10^−5^   
  \>1.5                              176/192   1.61    1.22--2.12   7.9 × 10^−4^  0.65
  **Vitamin B12 (*μ*g per day)**                                                  
  ⩽8.0                               213/192   1.64    1.25--2.14   3.4 × 10^−4^   
  \>8.0                              171/192   1.74    1.30--2.32   1.9 × 10^−4^  0.77
  **Alcohol drinking**                                                            
  Non-drinker                        240/232   1.76    1.37--2.26   1.0 × 10^−5^   
  Drinker                            142/152   1.56    1.13--2.14   6.3 × 10^−3^  0.56
  **MTHFR rs1801131**                                                             
  AA                                 252/254   1.60    1.26--2.02   1.2 × 10^−4^   
  AC+CC                              132/130   1.87    1.32--2.65   4.6 × 10^−4^  0.46
  **MTHFR rs1801133**                                                             
  CC                                 123/112   1.89    1.31--2.74   7.1 × 10^−4^   
  CT+TT                              261/272   1.61    1.27--2.03   6.4 × 10^−5^  0.46
  **MTR rs1805087**                                                               
  AA                                 235/257   1.82    1.42--2.34   2.2 × 10^−6^   
  AG+GG                              149/126   1.45    1.05--2.00      0.025      0.27
  **MTRR rs162049**                                                               
  GG                                 112/116   1.51    1.07--2.14      0.019       
  AG+GG                              272/266   1.77    1.40--2.25   2.6 × 10^−6^  0.46
  **MTRR rs10380**                                                                
  CC                                 291/302   1.78    1.42--2.24   5.3 × 10^−7^   
  CT+TT                               91/81    1.43    0.95--2.13      0.084      0.34

Abbreviations: CI=confidence interval; MTHFR=methylenetetrahydrofolate reductase; MTR=methionine synthase; MTRR=methionine synthase reductase; OR=odds ratio.

Adjusted for family history of breast cancer (no, yes), smoking (never, past, current), menopausal status (no, yes), physical activity in the last 5 years (no, ⩽2 days per week, ⩽4 days per week, ⩾5 days per week), number of births (0, 1, 2, 3, 4, \>5), vitamin use (no, yes), folate intake (continuous), alcohol drinking (non-drinker, occasional drinker, regular drinker of \<150 g ethanol per week, regular drinker of ⩾150 g ethanol per week), age (continuous), residential area (binary).
